Cited by 210Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchClusterin in disease pathology

Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease

Bertrand, Philippe, Poirier, Judes, Oda, Tomiichiro, Finch, Caleb E., Pasinetti, Giulio Maria·1995·Molecular Brain Research

Abstract

This study examines the relationship between the levels of apolipoprotein E (apoE) and apolipoprotein J (apoJ, also designated as clusterin) as a function of apoE genotype in the hippocampus and cortex of Alzheimer disease (AD) subjects. These two lipophilic proteins which are involved in the maintenance of lipid homeostasis are both synthesized in the brain by astrocytes. Results indicate a reduction of apoE levels in the hippocampus and frontal cortex that is proportional to the apoE4 allele dose. Conversely, apoJ (clusterin) levels were found to increase proportionately to the number of apoE4 allele dose. These results suggest a compensatory induction of apoJ (clusterin) in the brain of apoE4 AD subjects showing low brain levels of apoE.

Integrity signals

Registry

Crossref · 10.1016/0169-328x(95)00097-c

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The effect of the ε4 allele on locally synthesized CNS apoE protein levels is less clear, with conflicting reports showing reduced levels, no change, or increases in apoE from AD patient CNS and animal models.

    “The effect of the ␧4 allele on the locally synthesized CNS apoE protein levels is less clear with multiple conflicting reports showing either reduced levels (Bertrand et al., 1995;Beffert et al., 1999;Glo ¨ckner et al., 2002;Poirier, 2005;Ramaswamy et al., 2005), no change (Sullivan et al., 2004;Fryer et al., 2005) or increases (Fukumoto et al., 2003) in apoE from both AD patient CNS and animal mo”

    From Impact of Apolipoprotein E (ApoE) Polymorphism on Brain ApoE Levels (2008) · cites this paper as Bertrand et al., 1995

  • PICALM is involved in clathrin-mediated endocytosis, an essential step in intracellular trafficking of proteins and lipids.

    “It has been shown that like BIN1, PICALM is involved in clathrinmediated endocytosis (CME), an essential step in the intracellular trafficking of proteins and lipids such as nutrients, growth factors and neurotransmitters 36-38.”
  • A number of studies investigating apoE expression and protein levels in the brain parenchyma as a function of APOE genotype have yielded controversial results.

    “A number of studies investigating apoE expression and protein levels in the brain parenchyma as a function of APOE genotype have yielded controversial results (Beffert et al., 1999b; Bertrand et al., 1995; Bray et al., 2004; Growdon et al., 1999; Harr et al., 1996; Lambert et al., 1997; Pirttila et al., 1996).”

    From The role of apolipoprotein E in Alzheimer's disease (2009) · cites this paper as Bertrand et al., 1995

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Bertrand, P., Poirier, J., Oda, T., Finch, C. E., & Pasinetti, G. M.
Affiliations
  • McGill University (CA)
  • Douglas Mental Health University Institute (CA)
  • University of Southern California (US)
Corresponding author
Poirier, Judes
Venue
Molecular Brain Research
Publisher
Elsevier BV
Published
1995-10
Volume
33
Issue
1
Pages
174-178
ISSN
0169-328X (ISSN-L)
OpenAlex
W2070716601
Cited by
210
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 6 · 2023: 2 · 2022: 12 · 2021: 9 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 9 · 2015: 9 · 2014: 7 · 2013: 9 · 2012: 9
FWCI
7.76
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular Brain Research (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (5r01ag010003-03)
  • Medical Research Council
  • National Institute on Aging (AG10003-01)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Oncology › Clusterin in disease pathology
Keywords
apolipoprotein E, clusterin, Alzheimer's disease, hippocampus, frontal cortex, astrocytes, lipid homeostasis, gene expression
MeSH terms
Alzheimer Disease, Apolipoproteins E, Frontal Lobe, Genotype, Glycoproteins, Hippocampus, Humans, Nerve Tissue Proteins, Solubility, Case-Control Studies, Molecular Chaperones, Clusterin

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review